Giao dịch Astellas Pharma Inc. - 4503 CFD

Điều kiện giao dịch

• Loại: CFD
• Chênh lệch: 5.24
• Điều chỉnh phí tài trợ qua đêm cho vị thế mua: -0.01305%
• Điều chỉnh phí tài trợ qua đêm cho vị thế bán: -0.00917%
• Thời gian điều chỉnh phí tài trợ qua đêm: 22:00 (UTC)
• Tiền tệ: JPY
• Số lượng giao dịch tối thiểu: 1
• Biên lợi nhuận: 5.00%
• Sàn giao dịch chứng khoán: Japan
• Phí hoa hồng giao dịch: 0%
• Bảo đảm dừng phí bảo hiểm: 1%

Số liệu thống kê chính

• Trước đó Đóng: 2241.85
• Mở: 2241.35
• Thay đổi 1 năm: 50.95%
• Phạm vi trong ngày: 2241.35 - 2266.82

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. It offers XTANDI, an androgen receptor signaling inhibitor for the treatment of prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB); and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ transplant rejection. The company also provides Vesicare for OAB treatment; Eligard for prostate cancer treatment; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical collaboration agreement with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and Cytokinetics, Incorporated, as well as an agreement with BANDAI NAMCO Entertainment Inc. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.